WO2004041862A3 - Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor - Google Patents

Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor Download PDF

Info

Publication number
WO2004041862A3
WO2004041862A3 PCT/BE2003/000192 BE0300192W WO2004041862A3 WO 2004041862 A3 WO2004041862 A3 WO 2004041862A3 BE 0300192 W BE0300192 W BE 0300192W WO 2004041862 A3 WO2004041862 A3 WO 2004041862A3
Authority
WO
WIPO (PCT)
Prior art keywords
single domain
alpha
necrosis factor
antibodies directed
domain antibodies
Prior art date
Application number
PCT/BE2003/000192
Other languages
French (fr)
Other versions
WO2004041862A2 (en
Inventor
Karen Silence
Marc Lauwereys
Haard Hans De
Original Assignee
Ablynx Nv
Karen Silence
Marc Lauwereys
Haard Hans De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv, Karen Silence, Marc Lauwereys, Haard Hans De filed Critical Ablynx Nv
Priority to US10/534,348 priority Critical patent/US20060034845A1/en
Priority to CA2505316A priority patent/CA2505316C/en
Priority to JP2005502085A priority patent/JP2006524036A/en
Priority to CN200380108511.5A priority patent/CN1735629B/en
Priority to MXPA05004955A priority patent/MXPA05004955A/en
Priority to KR1020057008180A priority patent/KR101103218B1/en
Priority to BRPI0316092A priority patent/BRPI0316092B8/en
Priority to NZ540194A priority patent/NZ540194A/en
Priority to EP03776676.3A priority patent/EP1558647B1/en
Priority to AU2003286002A priority patent/AU2003286002B2/en
Priority to ES03776676.3T priority patent/ES2551682T3/en
Priority to NZ576284A priority patent/NZ576284A/en
Priority to PCT/BE2004/000002 priority patent/WO2004062551A2/en
Priority to KR1020057012413A priority patent/KR20050092029A/en
Priority to EP11162977A priority patent/EP2390270A1/en
Priority to KR1020087028177A priority patent/KR20080113286A/en
Priority to AU2004204262A priority patent/AU2004204262B2/en
Priority to ES04700953.5T priority patent/ES2542330T3/en
Priority to CA2512545A priority patent/CA2512545C/en
Priority to MXPA05006043A priority patent/MXPA05006043A/en
Priority to US10/541,708 priority patent/US9028816B2/en
Priority to BRPI0406694A priority patent/BRPI0406694B8/en
Priority to NZ540771A priority patent/NZ540771A/en
Priority to EP04700953.5A priority patent/EP1587838B1/en
Priority to JP2006500419A priority patent/JP2006517789A/en
Priority to RU2009109061/10A priority patent/RU2524129C2/en
Publication of WO2004041862A2 publication Critical patent/WO2004041862A2/en
Publication of WO2004041862A3 publication Critical patent/WO2004041862A3/en
Priority to IL168357A priority patent/IL168357A/en
Priority to IL169068A priority patent/IL169068A/en
Priority to NO20052769A priority patent/NO338986B1/en
Priority to NO20053774A priority patent/NO337265B1/en
Priority to HK05111896.7A priority patent/HK1082745A1/en
Priority to HK05111909.2A priority patent/HK1082746A1/en
Priority to US11/636,300 priority patent/US20070077249A1/en
Priority to US11/788,832 priority patent/US20070237769A1/en
Priority to US11/804,647 priority patent/US20090022721A1/en
Priority to JP2010164586A priority patent/JP5491308B2/en
Priority to US12/905,589 priority patent/US20110027281A1/en
Priority to US13/078,241 priority patent/US20110184150A1/en
Priority to IL218091A priority patent/IL218091A/en
Priority to US13/423,790 priority patent/US20120202977A1/en
Priority to US14/669,025 priority patent/US10112989B2/en
Priority to US16/142,063 priority patent/US11034755B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)

Abstract

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides.
PCT/BE2003/000192 2002-11-08 2003-11-07 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor WO2004041862A2 (en)

Priority Applications (42)

Application Number Priority Date Filing Date Title
US10/534,348 US20060034845A1 (en) 2002-11-08 2003-11-07 Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
CA2505316A CA2505316C (en) 2002-11-08 2003-11-07 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP2005502085A JP2006524036A (en) 2002-11-08 2003-11-07 Single domain antibodies targeting tumor necrosis factor alpha and uses thereof
CN200380108511.5A CN1735629B (en) 2002-11-08 2003-11-07 Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
MXPA05004955A MXPA05004955A (en) 2002-11-08 2003-11-07 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor.
KR1020057008180A KR101103218B1 (en) 2002-11-08 2003-11-07 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
BRPI0316092A BRPI0316092B8 (en) 2002-11-08 2003-11-07 single domain antibodies directed against tumor necrosis factor alpha and uses for them
NZ540194A NZ540194A (en) 2002-11-08 2003-11-07 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP03776676.3A EP1558647B1 (en) 2002-11-08 2003-11-07 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003286002A AU2003286002B2 (en) 2002-11-08 2003-11-07 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
ES03776676.3T ES2551682T3 (en) 2002-11-08 2003-11-07 Single domain antibodies directed against tumor necrosis factor-alpha and uses for them
BRPI0406694A BRPI0406694B8 (en) 2003-01-10 2004-01-09 therapeutic polypeptides, their homologues, their fragments, which are used in the modulations of platelet aggregation
US10/541,708 US9028816B2 (en) 2003-01-10 2004-01-09 Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
KR1020057012413A KR20050092029A (en) 2003-01-10 2004-01-09 Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf) or against collagen
EP11162977A EP2390270A1 (en) 2003-01-10 2004-01-09 Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
KR1020087028177A KR20080113286A (en) 2003-01-10 2004-01-09 Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf) or against collagen
AU2004204262A AU2004204262B2 (en) 2003-01-10 2004-01-09 Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
ES04700953.5T ES2542330T3 (en) 2003-01-10 2004-01-09 Therapeutic polypeptides, homologs thereof, fragments thereof and their use in modulating platelet-mediated aggregation
CA2512545A CA2512545C (en) 2003-01-10 2004-01-09 Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
MXPA05006043A MXPA05006043A (en) 2003-01-10 2004-01-09 Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation.
PCT/BE2004/000002 WO2004062551A2 (en) 2003-01-10 2004-01-09 RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
NZ576284A NZ576284A (en) 2003-01-10 2004-01-09 Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
NZ540771A NZ540771A (en) 2003-01-10 2004-01-09 Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
EP04700953.5A EP1587838B1 (en) 2003-01-10 2004-01-09 Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
JP2006500419A JP2006517789A (en) 2003-01-10 2004-01-09 Therapeutic polypeptides, homologues thereof, fragments thereof, and use in modulating platelet-mediated aggregation
RU2009109061/10A RU2524129C2 (en) 2003-01-10 2004-01-09 Therapeutic polypeptides, homologues thereof, fragments thereof and application thereof for modulation of platelet-mediated aggregation
IL168357A IL168357A (en) 2002-11-08 2005-05-03 Single domain antibodies directed against tumour necrosis factor-alpha and uses thereof
NO20052769A NO338986B1 (en) 2002-11-08 2005-06-08 The single-domain antibodies directed against tumor necrosis factor-alpha and applications thereof
IL169068A IL169068A (en) 2003-01-10 2005-06-08 Polypeptide or polypeptide construct comprising at least one single domain antibody directed against von willebrand factor, a composition comprising it, a nucleic acid encoding it and its uses in the preparation of a medicament for prevention and/or alleviation of conditions of platelet mediated aggregation
NO20053774A NO337265B1 (en) 2003-01-10 2005-08-08 A polypeptide construct directed against the von Willebrand factor, use of the polypeptide construct, compositions comprising the polypeptide construct, and method for its preparation.
HK05111909.2A HK1082746A1 (en) 2003-01-10 2005-12-22 Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
HK05111896.7A HK1082745A1 (en) 2002-11-08 2005-12-22 Single domain antibodies directed against tumour necrosis factor alpha and uses therefor
US11/636,300 US20070077249A1 (en) 2002-11-08 2006-12-08 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US11/788,832 US20070237769A1 (en) 2002-11-08 2007-04-20 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US11/804,647 US20090022721A1 (en) 2002-11-08 2007-05-18 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP2010164586A JP5491308B2 (en) 2003-01-10 2010-07-22 Therapeutic polypeptides, homologues thereof, fragments thereof, and use in modulating platelet-mediated aggregation
US12/905,589 US20110027281A1 (en) 2002-11-08 2010-10-15 Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
US13/078,241 US20110184150A1 (en) 2002-11-08 2011-04-01 Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
IL218091A IL218091A (en) 2003-01-10 2012-02-14 Polypeptide or polypeptide construct comprising at least one single domain antibody directed against von willebrand factor, a composition comprising it, a nucleic acid encoding it and uses thereof in the preparation of a medicament for prevention and/or alleviation of conditions of platelet-mediated aggregation
US13/423,790 US20120202977A1 (en) 2002-11-08 2012-03-19 Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
US14/669,025 US10112989B2 (en) 2003-01-10 2015-03-26 Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
US16/142,063 US11034755B2 (en) 2003-01-10 2018-09-26 Polypeptides and polypeptide constructs comprising single domain antibodies directed against von willebrand factor

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US42507302P 2002-11-08 2002-11-08
US42506302P 2002-11-08 2002-11-08
US60/425,073 2002-11-08
US60/425,063 2002-11-08
EP03447005.4 2003-01-10
EP03447005 2003-01-10
EPPCT/EP03/06581 2003-06-23
EPPCT/EP03/06581 2003-06-23
EPPCT/EP03/07313 2003-07-08
EPPCT/EP03/07313 2003-07-08

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/BE2003/000190 Continuation-In-Part WO2004041867A2 (en) 2002-11-08 2003-11-07 Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
PCT/BE2003/000194 Continuation-In-Part WO2004041863A2 (en) 2002-11-08 2003-11-07 Single domain antibodies directed against interferon- gamma and uses therefor

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/BE2003/000190 Continuation-In-Part WO2004041867A2 (en) 2002-11-08 2003-11-07 Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
PCT/BE2003/000194 Continuation-In-Part WO2004041863A2 (en) 2002-11-08 2003-11-07 Single domain antibodies directed against interferon- gamma and uses therefor
US11/636,300 Continuation US20070077249A1 (en) 2002-11-08 2006-12-08 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor

Publications (2)

Publication Number Publication Date
WO2004041862A2 WO2004041862A2 (en) 2004-05-21
WO2004041862A3 true WO2004041862A3 (en) 2004-06-24

Family

ID=32314976

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/BE2003/000192 WO2004041862A2 (en) 2002-11-08 2003-11-07 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
PCT/BE2003/000193 WO2004041865A2 (en) 2002-11-08 2003-11-07 Stabilized single domain antibodies
PCT/BE2003/000194 WO2004041863A2 (en) 2002-11-08 2003-11-07 Single domain antibodies directed against interferon- gamma and uses therefor

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/BE2003/000193 WO2004041865A2 (en) 2002-11-08 2003-11-07 Stabilized single domain antibodies
PCT/BE2003/000194 WO2004041863A2 (en) 2002-11-08 2003-11-07 Single domain antibodies directed against interferon- gamma and uses therefor

Country Status (11)

Country Link
US (7) US20060115470A1 (en)
EP (8) EP2258392A1 (en)
JP (5) JP2006524036A (en)
AU (1) AU2010226938B2 (en)
CA (3) CA2505316C (en)
HK (1) HK1082745A1 (en)
IL (1) IL168357A (en)
MX (1) MXPA05004955A (en)
NZ (4) NZ540195A (en)
RU (1) RU2704232C2 (en)
WO (3) WO2004041862A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules

Families Citing this family (373)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy-chain antibody
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1527346B1 (en) 2002-08-07 2011-06-08 Ablynx N.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US20060228355A1 (en) * 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
WO2010081856A1 (en) * 2009-01-14 2010-07-22 Ablynx Nv Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034833A1 (en) * 2002-11-08 2006-02-16 Els Beirnaert Single domain antibodies directed against interferron-gamma and uses therefor
EP1558647B1 (en) * 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
PT2316852E (en) * 2002-11-08 2014-06-23 Ablynx Nv Stabilized single domain antibodies
CA2512545C (en) 2003-01-10 2015-06-30 Karen Silence Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
CN1845938B (en) 2003-06-30 2010-05-26 杜门蒂斯有限公司 Polypeptides
EP1784427A2 (en) * 2004-06-01 2007-05-16 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
JP2008504356A (en) * 2004-06-30 2008-02-14 ドマンティス リミテッド Compositions and methods for treating inflammatory diseases
KR20130019457A (en) 2004-07-26 2013-02-26 다우 글로벌 테크놀로지스 엘엘씨 Process for improved protein expression by strain engineering
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CN101724071A (en) 2004-10-08 2010-06-09 杜门蒂斯有限公司 Single domain antibodies against TNFRl and methods of use therefor
CA2583017A1 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
EP2024396A2 (en) * 2004-12-02 2009-02-18 Domantis Limited Plad domain peptides with increased serum half life due to conjugation to domain antibodies
CA2589839C (en) 2004-12-02 2016-04-05 Unilever N.V. Method for affinity purification
MX2007006593A (en) * 2004-12-02 2008-03-04 Domantis Ltd ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES.
EP2769990A3 (en) * 2004-12-02 2015-02-25 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
SI1836500T1 (en) 2005-01-14 2010-11-30 Ablynx Nv METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
US8092800B2 (en) * 2005-03-18 2012-01-10 Istituto Superiore Di Sanita Antibodies against Candida antigens
LT2949668T (en) 2005-05-18 2019-11-11 Ablynx Nv Improved nanobodies tm against tumor necrosis factor-alpha
AU2012200682B2 (en) * 2005-05-18 2014-11-27 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
EP2007814A2 (en) 2005-05-20 2008-12-31 Ablynx N.V. Single domain vhh antibodies against von willebrand factor
DE102005023617A1 (en) * 2005-05-21 2006-11-23 Aspre Ag Method for mixing colors in a display
CA2619748C (en) 2005-08-30 2016-06-14 Actogenix Nv Novel treatment of chronic enterocolitis
US20090130776A1 (en) * 2005-09-01 2009-05-21 Canon Kabushiki Kaisha Binding protein molecule
EP1934611A2 (en) * 2005-09-23 2008-06-25 Academisch Ziekenhuis Leiden Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates
WO2007042524A2 (en) * 2005-10-14 2007-04-19 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
AR056806A1 (en) 2005-11-14 2007-10-24 Amgen Inc RANKL- PTH / PTHRP ANTIBODY CHEMICAL MOLECULES
JP2007172129A (en) * 2005-12-20 2007-07-05 Sony Corp Nonvolatile memory access control device and nonvolatile memory control system
US20110059101A9 (en) * 2006-03-13 2011-03-10 Ablynx N.V. Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
US20100226920A1 (en) * 2006-03-27 2010-09-09 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
WO2007112940A2 (en) * 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
WO2007118670A1 (en) * 2006-04-14 2007-10-25 Ablynx N.V. Dp-78-like nanobodies
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
CA2663042A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
US8703136B2 (en) 2006-10-10 2014-04-22 Regenesance B.V. Complement inhibition for improved nerve regeneration
CA2666511A1 (en) 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and uses thereof
US20100129354A1 (en) * 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
WO2008068280A1 (en) * 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
EP2097452A1 (en) * 2006-12-14 2009-09-09 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
PL2308514T3 (en) 2007-03-23 2013-11-29 To Bbb Holding B V Conjugates for targeted drug delivery across the blood-brain barrier
WO2008124858A2 (en) * 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
NZ581097A (en) 2007-05-24 2012-03-30 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
CA2691039A1 (en) * 2007-05-29 2008-12-11 Yale University Il-18 and protein kinase r inhibition for the treatment of copd
MX2009013137A (en) 2007-06-06 2010-04-30 Domantis Ltd Methods for selecting protease resistant polypeptides.
WO2009000006A1 (en) 2007-06-26 2008-12-31 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Display of binding agents
CA2691940C (en) 2007-07-03 2018-03-06 Joost Alexander Kolkman Methods for providing improved immunoglobulin sequences
CN104004088B (en) 2007-09-26 2017-11-07 Ucb医药有限公司 dual specificity antibody fusions
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
EP3192808A1 (en) 2007-11-27 2017-07-19 The University Of British Columbia 14-3-3 antagonists for the prevention and treatment of arthritis
US20110053865A1 (en) 2007-11-27 2011-03-03 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
EP2220115A2 (en) * 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
EP2080770A1 (en) * 2008-01-21 2009-07-22 MorphoSys AG Proteinaceous binding molecules comprising purification tags
EP2262530A4 (en) * 2008-03-03 2012-12-05 Dyax Corp Metalloproteinase 12 binding proteins
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
GB0805608D0 (en) * 2008-03-28 2008-04-30 Sec Dep For Environment Food & Detection method
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
JP2011516603A (en) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． Peptides capable of binding to serum proteins and compounds, constructs and polypeptides containing them
ES2620285T3 (en) 2008-05-02 2017-06-28 Novartis Ag Binding molecules based on improved fibronectin and their uses
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
SI2321352T1 (en) 2008-07-18 2016-04-29 Bristol-Myers Squibb Company Compositions monovalent for cd28 binding and methods of use
CN102164965B (en) 2008-09-26 2016-03-30 Ucb医药有限公司 Biological product
US9327022B2 (en) 2008-10-14 2016-05-03 National Research Council Of Canada BSA-specific antibodies
KR20110071139A (en) * 2008-10-21 2011-06-28 도만티스 리미티드 Ligands that have binding specificity for dc-sign
MX2011004558A (en) * 2008-10-29 2011-06-01 Wyeth Llc Methods for purification of single domain antigen binding molecules.
AU2013202856B2 (en) * 2008-10-29 2016-02-11 Ablynx N.V. Formulations of single domain antigen binding molecules
US8685895B2 (en) 2008-12-05 2014-04-01 Carolyn Enever Methods for selecting protease resistant polypeptides
CN102405236A (en) 2009-02-19 2012-04-04 葛兰素集团有限公司 Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
EP3828201A1 (en) 2009-04-30 2021-06-02 Ablynx N.V. Method for the production of domain antibodies
WO2010139808A2 (en) 2009-06-05 2010-12-09 Ablynx Nv IMPROVED AMINO ACID SEQUENCES DIRECTED AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (hRSV) AND POLYPEPTIDES COMPRISING THE SAME FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS
ES2804450T3 (en) 2009-07-10 2021-02-08 Ablynx Nv Method for producing variable domains
JP2012532619A (en) 2009-07-16 2012-12-20 グラクソ グループ リミテッド Antagonists, uses and methods for partially inhibiting TNFR1
SG177763A1 (en) 2009-07-28 2012-03-29 Hoffmann La Roche Non-invasive in vivo optical imaging method
JP2013500030A (en) 2009-07-29 2013-01-07 グラクソ グループ リミテッド Ligands that bind TGF-β receptor RII
EP2473528B1 (en) 2009-09-03 2014-12-03 Ablynx N.V. Stable formulations of polypeptides and uses thereof
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
US20110195494A1 (en) 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
EP2486056A1 (en) 2009-10-09 2012-08-15 Ablynx N.V. Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
DK2491056T3 (en) * 2009-10-22 2021-10-25 Univ Twente VHH FOR USE IN TISSUE REPAIR, ORGAN REGENERATION, ORGAN REPLACEMENT AND TISSUE CONSTRUCTION
AR078763A1 (en) 2009-10-27 2011-11-30 Glaxo Group Ltd ANTI FACTOR TUMOR NECROSIS POLYPEPTIDES 1 (ANTI-TNFR1) STABLE, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051333A1 (en) 2009-10-30 2011-05-05 Novartis Ag Universal fibronectin type iii bottom-side binding domain libraries
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
US8962807B2 (en) 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
TWI513466B (en) 2010-01-20 2015-12-21 Boehringer Ingelheim Int Anticoagulant antidotes
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011098518A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
EP3501499B1 (en) 2010-02-11 2022-09-07 Ablynx NV Methods and compositions for the preparation of aerosols
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
AU2011231558B2 (en) 2010-03-26 2016-08-11 Westfaelische Wilhelms-Universitaet Muenster Substitute therapy for glucocorticoids
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
SG185416A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
BR112012028006A2 (en) 2010-05-07 2016-08-02 Hoffmann La Roche immunohistochemistry (ihq) method, use of a therapeutically active binding domain, kit and binding domain
NZ603570A (en) 2010-05-20 2014-12-24 Ablynx Nv Biological materials related to her3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
AU2011277983C1 (en) 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
EP3248987A1 (en) 2010-07-30 2017-11-29 Novartis AG Fibronectin cradle molecules and libraries thereof
UA114883C2 (en) 2010-08-20 2017-08-28 Новартіс Аг Antibodies for epidermal growth factor receptor 3 (her3)
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
WO2012056000A1 (en) 2010-10-29 2012-05-03 Ablynx Nv Method for the production of immunoglobulin single variable domains
BR112013011003B1 (en) 2010-11-08 2021-12-07 Novartis Ag POLYPEPTIDE AND ITS USES, TRANSGENIC HOST CELL OF MICROORGANISM, MONOVALENT, BIVALENT, MULTIVALENT, BIPARATOPIC OR MULTIPARATOPIC NANOBODY, AND PHARMACEUTICAL COMPOSITION
EP2643349B1 (en) 2010-11-26 2019-09-04 Molecular Partners AG Designed repeat proteins binding to serum albumin
PE20140982A1 (en) 2011-01-06 2014-08-22 Glaxo Group Ltd LINKS THAT JOIN THE TRANSFORMANT GROWTH FACTOR-BETA RECEPTOR II
JP6385060B2 (en) 2011-03-07 2018-09-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト In vivo selection of therapeutically active antibodies
EP2683290B1 (en) 2011-03-07 2018-11-07 F.Hoffmann-La Roche Ag Methods for in vivo testing of therapeutic antibodies
PT2691415T (en) 2011-03-28 2018-10-19 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
AU2012234284B2 (en) 2011-03-28 2015-10-08 Ablynx Nv Bispecific anti-CXCR7 immunoglobulin single variable domains
MX361242B (en) 2011-03-30 2018-11-30 Ablynx Nv Methods of treating immune disorders with single domain antibodies against tnf-alpha.
EA201301090A1 (en) 2011-03-30 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх ANTI-AUDIO ANTICOAGULANTS
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
US9534039B2 (en) 2011-05-09 2017-01-03 Ablynx N.V. Method for the production of immunoglobulin single variable domains
CA2835340A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
US9580480B2 (en) 2011-05-31 2017-02-28 Massachusetts Institute Of Technology Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
KR102240318B1 (en) 2011-06-23 2021-04-15 아블린쓰 엔.브이. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN104271598A (en) 2011-06-23 2015-01-07 埃博灵克斯股份有限公司 Immunoglobulin single variable domains directed against IgE
JP6324887B2 (en) 2011-06-23 2018-05-16 アブリンクス エン．ヴェー． Proteins that bind to serum albumin
EP3839049A3 (en) 2011-09-19 2021-10-20 Kymab Limited Antibodies, variable domains & chains tailored for human use
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CN103889451B (en) 2011-09-30 2016-06-29 埃博灵克斯股份有限公司 The biological substance relevant to C-Met
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
EP3290442A1 (en) 2011-11-04 2018-03-07 Novartis AG Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
UY34487A (en) 2011-12-05 2013-07-31 Novartis Ag ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEIVER 3 (HER3)
BR112014013568A2 (en) 2011-12-05 2017-06-13 Novartis Ag epidermal growth factor 3 (her3) receptor antibodies directed to her3 domain ii
WO2013102659A2 (en) * 2012-01-06 2013-07-11 Complix Nv Binding agents to intracellular target molecules
MX350248B (en) 2012-03-30 2017-08-31 Boehringer Ingelheim Int Ang2-binding molecules.
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
NZ701573A (en) 2012-05-17 2017-04-28 Extend Biosciences Inc Carriers for improved drug delivery
AU2013265665B2 (en) 2012-05-24 2017-10-26 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
CA2878712A1 (en) * 2012-08-31 2014-03-06 arGEN-X BV Method for producing antibody molecules having inter-species, intra-target cross-reactivity
US20140161796A1 (en) * 2012-09-13 2014-06-12 Andreas Loew Single chain proteins with c-terminal modifications
RU2530553C2 (en) * 2012-11-07 2014-10-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Recombinant single-domain antibody able to bind human tumour necrosis factor specifically and its derivatives
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
EP2752426A1 (en) 2013-01-03 2014-07-09 Covagen AG Human serum albumin binding compounds and fusion proteins thereof
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
CN112858672A (en) 2013-01-30 2021-05-28 弗拉芒区生物技术研究所 Novel chimeric polypeptides for screening and drug discovery purposes
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
ES2745772T3 (en) 2013-02-05 2020-03-03 Vib Vzw Acetylcholine Muscarinic Receptor Binding Agents and Uses thereof
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
JP2016514130A (en) 2013-03-14 2016-05-19 ノバルティス アーゲー Antibody against Notch3
US9617339B2 (en) 2013-03-15 2017-04-11 Vib Vzw Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain
PT2992100T (en) 2013-04-29 2019-12-16 Agrosavfe Nv Agrochemical compositions comprising antibodies binding to sphingolipids
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
EP3019192A4 (en) 2013-07-08 2017-07-05 Nanjingjinsirui Science&Technology Biology Corporation Compositions and methods for increasing protein half-life in a serum
CN103454413B (en) * 2013-09-04 2015-03-11 吉日木图 Bactrian camel specific antibody preparation method and immune detection method
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
JP6793902B2 (en) 2013-12-20 2020-12-02 ノバルティス アーゲー Adjustable chimeric antigen receptor
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
AU2015261536B2 (en) 2014-05-16 2020-05-07 Ablynx Nv Improved immunoglobulin variable domains
AU2015261467B2 (en) 2014-05-16 2020-12-17 Ablynx Nv Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3194976B1 (en) 2014-07-22 2020-04-01 Vib Vzw Methods to select agents that stabilize protein complexes
CN106573983B (en) 2014-07-29 2018-05-25 布鲁塞尔自由大学 For the radiolabeled antibody fragment used in the prevention and/or treatment of cancer
WO2016016329A1 (en) 2014-07-29 2016-02-04 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
EP3174546B1 (en) 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
WO2016029043A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
RU2017116710A (en) 2014-10-23 2018-11-23 Сингх Биотекнолоджи, Ллк SINGLE-DOMAIN ANTIBODIES AIMED AGAINST EXTRACELLULAR ANTIGENES
CA2966548A1 (en) 2014-11-05 2016-05-12 Agrosavfe Nv Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
CA2981096A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Tnf-alpha binding polypeptides
AU2016259792B2 (en) 2015-05-13 2019-07-25 Ablynx N.V. T cell recruiting polypeptides based on TCR alpha/beta reactivity
JP7163028B2 (en) 2015-05-13 2022-10-31 アブリンクス エン．ヴェー． T cell recruiting polypeptides based on CD3 reactivity
CA2986254A1 (en) 2015-05-18 2016-11-24 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
ES2889906T3 (en) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Trispecific binding proteins and medical uses
US11298433B2 (en) 2015-07-17 2022-04-12 Vrije Universiteit Brussel Radiolabelled antibody fragments for use in treating cancer
EA034582B1 (en) 2015-08-07 2020-02-21 АЭлЭкс ОНКОЛОДЖИ ИНК. Sirp-alpha variant constructs and use thereof
DK3331902T3 (en) 2015-08-07 2021-07-26 Alx Oncology Inc CONSTRUCTIONS WITH A SIRP ALPHA DOMAIN OR VARIANT THEREOF
TWI746473B (en) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 Single domain antibodies directed against intracellular antigens
NO2768984T3 (en) * 2015-11-12 2018-06-09
HUE057241T2 (en) 2015-11-13 2022-04-28 Ablynx Nv Improved serum albumin-binding immunoglobulin variable domains
WO2017087391A1 (en) * 2015-11-17 2017-05-26 Bayer Healthcare, Llc Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
JP7046804B2 (en) 2015-11-18 2022-04-04 アブリンクス エン．ヴェー． Improved serum albumin binder
WO2017087587A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. PD1/CTLA4 Binders
EP3377527A1 (en) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. Ctla4 binders
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
CN108473561B (en) 2015-11-27 2022-12-16 埃博灵克斯股份有限公司 Polypeptide inhibiting CD40L
KR20180098671A (en) * 2016-01-11 2018-09-04 인히브릭스, 인크. Multivalent and multispecific OX40-binding fusion proteins
US11505599B2 (en) 2016-01-14 2022-11-22 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for Foxp3-derived peptides
EP3411397A1 (en) 2016-02-05 2018-12-12 Orionis Biosciences NV Cd8 binding agents
CA3016849A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
WO2017182603A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017182605A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
US20190127447A1 (en) 2016-05-02 2019-05-02 Ablynx N.V. Treatment of rsv infection
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
DK3458478T3 (en) 2016-05-18 2021-03-22 Boehringer Ingelheim Int ANTI-PD-1 AND ANTI-LAG3 ANTIBODIES FOR CANCER TREATMENT
CA3024683A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
EA201892691A1 (en) 2016-05-20 2019-04-30 Харпун Терапьютикс, Инк. SINGLE-DOMAIN PROTEIN, BINDING SERUM ALBUMIN
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7150618B2 (en) 2016-06-23 2022-10-11 アブリンクス エン．ヴェー． Improved Pharmacokinetic Assays for Immunoglobulin Single Variable Domains
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
CA3032498A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
WO2018050833A1 (en) 2016-09-15 2018-03-22 Ablynx Nv Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
CN109689686B (en) 2016-10-07 2020-08-25 T细胞受体治疗公司 Compositions and methods for T cell receptor weight programming using fusion proteins
EP3541846A1 (en) 2016-11-16 2019-09-25 Ablynx NV T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
AU2017363302A1 (en) 2016-11-23 2019-06-27 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
EP3544997A4 (en) 2016-11-23 2020-07-01 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
KR20230061582A (en) 2016-12-07 2023-05-08 아블린쓰 엔.브이. Improved serum albumin binding immunoglobulin single variable domains
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
CN107674122A (en) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 A kind of single domain antibody for identifying human serum albumins
KR20240013861A (en) 2017-01-17 2024-01-30 아블린쓰 엔.브이. Improved serum albumin binders
AU2018209150A1 (en) 2017-01-17 2019-07-25 Ablynx Nv Improved serum albumin binders
GB201701404D0 (en) * 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
US11384154B2 (en) 2017-02-06 2022-07-12 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
EP3589725A1 (en) 2017-02-28 2020-01-08 Vib Vzw Means and methods for oral protein delivery
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
KR20190129077A (en) 2017-03-15 2019-11-19 팬디온 테라퓨틱스, 인코포레이티드 Targeted Immune Tolerance
JP2020512348A (en) 2017-03-30 2020-04-23 デューク ユニバーシティ Radiolabeled biomolecules and uses thereof
SG11201908154RA (en) 2017-03-31 2019-10-30 Ablynx Nv Improved immunogenicity assays
CA3058290A1 (en) 2017-04-18 2018-10-25 Universite Libre De Bruxelles Biomarkers and targets for proliferative diseases
KR20200005635A (en) 2017-05-11 2020-01-15 브이아이비 브이지더블유 Glycosylation of Variable Immunoglobulin Domains
KR102376863B1 (en) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. mesothelin binding protein
CN110913908B (en) 2017-05-12 2022-05-27 哈普恩治疗公司 MSLN-targeting trispecific proteins and methods of use
CN111010866A (en) 2017-05-24 2020-04-14 潘迪恩治疗公司 Targeted immune tolerance
US20200190216A1 (en) 2017-06-02 2020-06-18 Merck Patent Gmbh Mmp13 binding immunoglobulins
EP3630818A1 (en) 2017-06-02 2020-04-08 Ablynx NV Aggrecan binding immunoglobulins
MX2019014400A (en) 2017-06-02 2020-02-10 Merck Patent Gmbh Adamts binding immunoglobulins.
EP3630817A1 (en) 2017-06-02 2020-04-08 Merck Patent GmbH Polypeptides binding adamts5, mmp13 and aggrecan
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
JP2020532285A (en) 2017-07-11 2020-11-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド Polypeptides that bind to complement component C5 or serum albumin and their fusion proteins
JP7241731B2 (en) 2017-07-19 2023-03-17 フエー・イー・ベー・フエー・ゼツト・ウエー serum albumin binder
CN111465612A (en) 2017-10-13 2020-07-28 哈普恩治疗公司 B cell maturation antigen binding proteins
CR20200196A (en) 2017-10-13 2020-06-05 Harpoon Therapeutics Inc Trispecific proteins and methods of use
CA3076791A1 (en) 2017-10-31 2019-05-09 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN109970860A (en) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 Three chain antibodies, Its Preparation Method And Use
EP3749295A4 (en) 2018-02-05 2022-04-27 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019166622A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
BR112020018908A2 (en) 2018-03-23 2021-01-26 Université Libre de Bruxelles wnt signaling agonist molecules
WO2019185723A1 (en) 2018-03-27 2019-10-03 Umc Utrecht Holding B.V. Targeted thrombolysis for treatment of microvascular thrombosis
KR20210021467A (en) 2018-05-14 2021-02-26 웨어울프 세라퓨틱스, 인크. Activatable interleukin-2 polypeptide and method of use thereof
SG11202011309SA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable interleukin 12 polypeptides and methods of use thereof
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
JP7122672B2 (en) * 2018-06-08 2022-08-22 パナソニックＩｐマネジメント株式会社 VHH antibodies
WO2020023888A2 (en) * 2018-07-26 2020-01-30 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using target specific fusion proteins
KR20210044243A (en) 2018-08-13 2021-04-22 인히브릭스, 인크. OX40 binding polypeptides and uses thereof
JP7190675B2 (en) * 2018-08-23 2022-12-16 パナソニックＩｐマネジメント株式会社 Antibody and complex that bind to norovirus, detection device and detection method using the same
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
EP4321530A3 (en) 2018-09-27 2024-05-22 Xilio Development, Inc. Masked cytokine polypeptides
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
WO2020114616A1 (en) * 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
CN111423509B (en) * 2019-01-10 2021-07-09 瑞阳(苏州)生物科技有限公司 Affinity chromatography purification method of anti-HSA single domain antibody and fusion protein thereof
AU2020266750A1 (en) 2019-04-29 2021-11-25 Confo Therapeutics N.V. Screening methods and assays for use with transmembrane proteins, in particular with GPCRS
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
AU2020275877A1 (en) 2019-05-14 2021-12-23 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
EP3976067A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
BR112021024003A2 (en) 2019-05-31 2022-04-19 Alx Oncology Inc Cancer treatment methods with sirp alpha-fc fusion in combination with an immune checkpoint inhibitor
CN114514243A (en) 2019-06-21 2022-05-17 索瑞索制药公司 Polypeptides
CN114466864A (en) 2019-06-21 2022-05-10 索瑞索制药公司 Polypeptides
AU2020295767A1 (en) 2019-06-21 2022-02-17 Sorriso Pharmaceuticals, Inc. Compositions
TW202128775A (en) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 Pd-l1 inhibitor - tgfβ inhibitor bispecific drug moieties
WO2021078786A1 (en) 2019-10-21 2021-04-29 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
CA3160506A1 (en) 2019-11-11 2021-05-20 Ibi-Ag Innovative Bio Insecticides Ltd. Insect control nanobodies and uses thereof
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
AU2020396204A1 (en) 2019-12-06 2022-07-28 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting TNFα and IL-23
MX2022006881A (en) 2019-12-06 2022-07-11 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l.
CN114980974A (en) 2019-12-09 2022-08-30 艾伯霖克斯公司 Polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
CA3165429A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
MX2022010175A (en) 2020-02-21 2022-09-12 Harpoon Therapeutics Inc Flt3 binding proteins and methods of use.
WO2021170540A1 (en) 2020-02-25 2021-09-02 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
KR20220153604A (en) 2020-03-11 2022-11-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Methods and Compositions for Gene Delivery Using Engineered Viral Particles
CN113461824A (en) 2020-03-31 2021-10-01 普米斯生物技术(珠海)有限公司 Platform for constructing multispecific antibody
WO2021198396A1 (en) 2020-03-31 2021-10-07 Biotalys NV Anti-fungal polypeptides
WO2021213435A1 (en) 2020-04-22 2021-10-28 迈威(上海)生物科技股份有限公司 Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
CN116249555A (en) 2020-05-19 2023-06-09 勃林格殷格翰国际有限公司 Binding molecules for cancer treatment
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
IL300173A (en) 2020-07-31 2023-03-01 Biotalys NV Expression host
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
CA3195687A1 (en) 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
AR123862A1 (en) 2020-10-21 2023-01-18 Boehringer Ingelheim Int ANTI-VEGF AND ANTI-TRKB BISPECIFIC BINDING MOLECULES FOR THE TREATMENT OF OCULAR DISEASES
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024508207A (en) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ LTBR agonists in combination therapy against cancer
KR20230123497A (en) 2020-12-18 2023-08-23 아블린쓰 엔.브이. Polypeptide comprising an immunoglobulin single variable domain targeting IL-6 and TNF-α
MX2023007308A (en) 2020-12-18 2023-07-04 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor.
EP4263610A1 (en) 2020-12-18 2023-10-25 Ablynx N.V. T cell recruiting polypeptides based on tcr alpha/beta reactivity
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
WO2022136649A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Non-blocking human ccr8 binders
WO2022136647A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Human ccr8 binders
EP4267621A1 (en) 2020-12-24 2023-11-01 Vib Vzw Murine cross-reactive human ccr8 binders
CN117794566A (en) 2021-02-05 2024-03-29 Vib研究所 Sha Bei viral binding agents
US20240101647A1 (en) 2021-02-05 2024-03-28 Vib Vzw Sarbecovirus binders
US20240130999A1 (en) 2021-02-17 2024-04-25 Vib Vzw Inhibition of SLC4A4 in the Treatment of Cancer
CA3211270A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2022242892A1 (en) 2021-05-17 2022-11-24 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
US20220411533A1 (en) 2021-06-17 2022-12-29 Boehringer Ingelheim International Gmbh Novel Tri-specific Binding Molecules
WO2022268993A1 (en) 2021-06-23 2022-12-29 Vib Vzw Means and methods for selection of specific binders
EP4365199A1 (en) 2021-06-29 2024-05-08 Shandong Simcere Biopharmaceutical Co., Ltd. Cd16 antibody and use thereof
EP4377352A2 (en) 2021-07-30 2024-06-05 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
CN117751143A (en) 2021-07-30 2024-03-22 山东先声生物制药有限公司 anti-PVRIG/anti-TIGIT bispecific antibodies and uses
WO2023057601A1 (en) 2021-10-06 2023-04-13 Biotalys NV Anti-fungal polypeptides
TW202334196A (en) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1 binding polypeptides
TW202332694A (en) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 Serum half-life extended pd-l1 binding polypeptides
WO2023098846A1 (en) 2021-12-03 2023-06-08 江苏先声药业有限公司 Anti-bcma nanobody and use thereof
AU2022409802A1 (en) 2021-12-15 2024-06-06 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof
WO2023111266A1 (en) 2021-12-17 2023-06-22 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
WO2023130123A2 (en) * 2022-01-03 2023-07-06 Twist Bioscience Corporation Bispecific sars-cov-2 antibodies and methods of use
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023148291A1 (en) 2022-02-02 2023-08-10 Biotalys NV Methods for genome editing
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023213751A1 (en) 2022-05-02 2023-11-09 Umc Utrecht Holding B.V Single domain antibodies for the detection of plasmin-cleaved vwf
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
WO2023222825A1 (en) 2022-05-18 2023-11-23 Vib Vzw Sarbecovirus spike s2 subunit binders
US20240109965A1 (en) 2022-06-14 2024-04-04 Ablynx N.V. Immunoglobulin single variable domains targeting t cell receptor
WO2024003873A1 (en) * 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
US20240052065A1 (en) 2022-07-15 2024-02-15 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024100093A1 (en) 2022-11-09 2024-05-16 Merck Patent Gmbh Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity
WO2024105091A1 (en) 2022-11-15 2024-05-23 Imec Vzw Method and system for droplet manipulation
WO2024126805A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002078A1 (en) * 1989-08-07 1991-02-21 Peptide Technology Ltd Tumour necrosis factor binding ligands
WO2002057445A1 (en) * 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2002079781A1 (en) * 2001-03-28 2002-10-10 Heska Corporation Methods of detecting early renal disease in animals

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US460167A (en) 1891-09-29 Car-mover
SE307996B (en) 1965-11-30 1969-01-27 Asea Ab
CU22545A1 (en) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4405306A (en) 1981-12-08 1983-09-20 Beecham Inc. Medicated disposable douche product
US4498758A (en) 1982-05-26 1985-02-12 Agfa-Gevaert N.V. Apparatus for transferring xerographic images
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (en) 1983-08-30 1985-04-24 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4946788A (en) 1985-06-11 1990-08-07 Ciba-Geigy Corporation Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
US4714759A (en) 1985-12-02 1987-12-22 Whitaker Jr Robert B Immunotoxin therapy of allergy
JPS62175426A (en) 1986-01-27 1987-08-01 Kazufumi Shimizu Antibody and spraying agent containing said substance as active component
US5075236A (en) 1987-04-24 1991-12-24 Teijin Limited Method of detecting kawasaki disease using anti-tumor necrosis antibody
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4940782A (en) 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
DE3853740T2 (en) 1987-06-10 1995-11-09 Dana Farber Cancer Inst Inc Bifunctional antibody designs and methods for the selective killing of cell populations.
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US4962035A (en) 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
US5252467A (en) 1987-12-31 1993-10-12 Tanox Biosystems, Inc. Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE
US5231026A (en) 1987-12-31 1993-07-27 Tanox Biosystems, Inc. DNA encoding murine-human chimeric antibodies specific for antigenic epitopes of IgE present on the extracellular segment of the membrane domain of membrane-bound IgE
US5428133A (en) 1987-12-31 1995-06-27 Tanox Biosystems, Inc. Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
EP0617127A1 (en) 1987-12-31 1994-09-28 Tanox Biosystems, Inc. Antigenic epitopes on B cell-bound IgE Immunoglobulins
US5422258A (en) 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
JPH01268645A (en) 1988-04-18 1989-10-26 Teijin Ltd Agent for suppressing schwartzman reaction
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP0366043B1 (en) 1988-10-24 1994-03-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibody
AU634186B2 (en) * 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (en) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Use of stabilized protein or peptide conjugates for the preparation of a drug
US6451983B2 (en) 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
US5644034A (en) 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
US5196193A (en) 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9012995D0 (en) 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
GB9016299D0 (en) 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
JP2988635B2 (en) 1990-09-18 1999-12-13 塩野義製薬株式会社 Monoclonal antibody against human IgE
US5843440A (en) * 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
AU8869291A (en) * 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
JP3464215B2 (en) 1991-03-21 2003-11-05 マシモ・コーポレイション Low noise optical probe
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH06508371A (en) 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ Orally administrable therapeutic protein and its production method
JP3457962B2 (en) 1991-08-14 2003-10-20 ジェネンテク，インコーポレイテッド Immunoglobulin variants for specific Fcε receptors
ES2202310T3 (en) 1991-12-13 2004-04-01 Xoma Corporation METHODS AND MATERIALS FOR THE PREPARATION OF VARIABLE DOMAINS OF MODIFIED ANTIBODIES AND THEIR THERAPEUTIC USES.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0584421A1 (en) 1992-08-21 1994-03-02 Cécile Casterman Immunoglobulins devoid of light chains
DE69330523T4 (en) * 1992-08-21 2012-08-23 Vrije Universiteit Brussel IMMUNOGLOBULINE WITHOUT LIGHT CHAINS
ES2121907T3 (en) 1992-08-28 1998-12-16 Bayer Ag USE OF ANTI-TNF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF BACTERIAL MENINGITIS.
EP1452542A3 (en) 1992-09-24 2007-05-02 Novartis AG Reshaped human monoclonal antibodies specific for IgE
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
EP0663836B1 (en) 1992-10-08 1997-07-09 The Kennedy Institute Of Rheumatology Treatment of autoimmune and inflammatory disorders
GB9221657D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
JPH07508763A (en) * 1992-11-20 1995-09-28 シェリング・コーポレーション Antagonist of human gamma interferon
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
EP0695189B1 (en) 1992-12-29 1998-11-25 Genentech, Inc. Treatment of inflammatory bowel disease with ifn-gamma inhibitors
DE69411154T2 (en) 1993-02-22 1998-10-22 Alza Corp AGENT FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
DE122009000074I1 (en) 1993-03-05 2011-12-01 Bayer Healthcare Ag Human monoclonal anti-TNF alpha antibody.
US6838254B1 (en) * 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
EP0698097B1 (en) 1993-04-29 2001-08-16 Unilever N.V. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
GB9311454D0 (en) 1993-06-03 1993-07-21 Agricultural & Food Res Pharmaceutical compositions
AU1441395A (en) 1993-12-21 1995-07-10 St. Louis University Ocular diagnostics and therapies
DE69501817T2 (en) * 1994-01-18 1998-09-10 Genentech Inc METHOD FOR TREATING PARASITAL INFECTIONS USING IGE ANTAGONISTS
US5747148A (en) 1994-09-12 1998-05-05 Minnesota Mining And Manufacturing Company Ink jet printing sheet
DK0795608T3 (en) 1994-11-30 2003-07-21 Ajinomoto Kk Antithrombotic agent and monoclonal anti-von Willebrand factor antibodies
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
AU6267896A (en) * 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US5637038A (en) 1995-07-10 1997-06-10 Davis; James F. Apparatus and method for skinning poultry
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
GB9518323D0 (en) 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
WO1997011177A1 (en) * 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
DE122004000004I1 (en) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Human antibodies that bind to human TNFalpha.
AU740043B2 (en) 1996-06-27 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
IT1289608B1 (en) 1997-02-05 1998-10-15 Angelini Ricerche Spa COMPOSITION FOR THERAPEUTIC OR DIAGNOSTIC USE ADMINISTRABLE VIA INTRANASAL, SUBLINGUAL OR VAGINAL
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
AUPO561697A0 (en) 1997-03-13 1997-04-10 Crc For Cardiac Technology Haemocompatible surfaces
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
DE29712318U1 (en) 1997-07-07 1997-10-02 Arnold, Günter, 24977 Langballig Paring knife
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
DE69841562D1 (en) * 1997-10-27 2010-04-29 Bac Ip Bv MULTIVALENT ANTIGENBINDING PROTEINS
US20020076404A1 (en) * 1998-01-29 2002-06-20 Chang Tse Wen Treating atopic dermatitis with IgE antagonists
EP0954978B1 (en) 1998-03-12 2011-11-30 VHsquared Limited New products comprising inactivated yeasts or moulds provided with active antibodies
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
CZ121599A3 (en) * 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Single-chain molecule binding several antigens, process of its preparation and medicament in which the molecule is comprised
AU775483B2 (en) * 1998-06-10 2004-08-05 Promega Corporation Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
JP3495987B2 (en) 1998-07-06 2004-02-09 エーロスクレーン エッス．アー． Method for high-throughput screening characterization and / or dose determination of agonists and / or antagonists for calcium binding receptors
US6149934A (en) * 1999-04-23 2000-11-21 Kimberly-Clark Worldwide, Inc. Absorbent article having a lotionized bodyside liner
CA2343840C (en) 1998-10-20 2011-03-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
JP2002529373A (en) 1998-10-23 2002-09-10 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド Conformation-specific anti-von Willebrand factor antibody
EP1002861A1 (en) 1998-10-26 2000-05-24 Unilever Plc Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
DE19852800C1 (en) 1998-11-16 2000-04-13 Univ Albert Ludwigs Freiburg Production of antibodies to a polypeptide encoded by a known DNA sequence comprises binding of antibodies produced by DNA vaccination to immobilized recombinantly expressed polypeptide
ATE477273T1 (en) 1998-12-01 2010-08-15 Facet Biotech Corp HUMANIZED ANTIBODIES AGAINST GAMMA INTERFERON
DK1140170T3 (en) 1999-01-05 2006-10-23 Univ Southern Australia Antibody fragments for topical treatment of eye diseases
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
BR0009323A (en) 1999-03-25 2002-01-08 Knoll Gmbh Human antibodies that bind human il-12 and methods for production
AU776824B2 (en) 1999-04-22 2004-09-23 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
US6436401B1 (en) * 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
JP2003509438A (en) 1999-09-16 2003-03-11 ユニリーバー・ナームローゼ・ベンノートシヤープ Anti-dandruff delivery system
EP1118669A3 (en) 1999-12-17 2001-08-29 Unilever Plc Production of camelid antibodies in plants
CA2921260A1 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
KR101111103B1 (en) 2000-02-10 2012-02-13 아보트 러보러터리즈 Antibodies that bind human interleukin-18 and methods of making and using
ATE428733T1 (en) 2000-03-14 2009-05-15 Unilever Nv VARIABLE DOMAIN OF THE HEAVY CHAIN OF AN ANTIBODY TO HUMAN NUTRITIONAL LIPASES AND THEIR USES
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
WO2001080883A1 (en) 2000-04-26 2001-11-01 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
WO2001089567A1 (en) 2000-05-22 2001-11-29 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
EP1967205B1 (en) * 2000-08-30 2012-10-10 Pfizer Products Inc. Anti-IgE vaccines
WO2002020615A2 (en) 2000-09-08 2002-03-14 Micromet Ag Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
JP2004529610A (en) * 2000-10-13 2004-09-30 ユーエイビー リサーチ ファンデーション Human anti-epidermal growth factor receptor single chain antibody
AU2002236572A1 (en) * 2000-11-03 2002-05-21 Board Of Regents, The University Of Texas System Methods for detecting the efficacy of anticancer treatments
AU2002229639A1 (en) 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
GB0031448D0 (en) * 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050019324A1 (en) * 2001-03-29 2005-01-27 Wreschner Daniel H. Peptides and antibodies to muc 1 proteins
US8178098B2 (en) * 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US7638598B2 (en) * 2001-04-06 2009-12-29 The Trustees Of The University Of Pennsylvania ErbB interface peptidomimetics and methods of use thereof
EP2335728A1 (en) 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
AU2002319402B2 (en) * 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
JP2005289809A (en) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy-chain antibody
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
US20040063912A1 (en) 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
AU2002316574B2 (en) 2002-03-15 2008-05-01 Brandeis University Central airway administration for systemic delivery of therapeutics
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
AU2003248982B2 (en) 2002-08-01 2009-12-10 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
CA2505316C (en) 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US20060034833A1 (en) * 2002-11-08 2006-02-16 Els Beirnaert Single domain antibodies directed against interferron-gamma and uses therefor
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20100003253A1 (en) 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
PT2316852E (en) * 2002-11-08 2014-06-23 Ablynx Nv Stabilized single domain antibodies
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN1845938B (en) * 2003-06-30 2010-05-26 杜门蒂斯有限公司 Polypeptides
DK1735348T3 (en) * 2004-03-19 2012-07-16 Imclone Llc Human anti-epidermal growth factor receptor antibody
US8105592B2 (en) 2004-11-25 2012-01-31 Vhsquared Limited Heavy chain and single domain antibodies
MX2007006593A (en) 2004-12-02 2008-03-04 Domantis Ltd ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES.
LT2949668T (en) 2005-05-18 2019-11-11 Ablynx Nv Improved nanobodies tm against tumor necrosis factor-alpha
DE102005023617A1 (en) 2005-05-21 2006-11-23 Aspre Ag Method for mixing colors in a display
EP1754955B1 (en) 2005-08-19 2015-05-06 Aisin Aw Co., Ltd. Navigation method and corresponding system for determining a travel related time
TW200738750A (en) 2005-12-06 2007-10-16 Domantis Ltd Ligands and methods of use therefor
EP2220115A2 (en) 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
JP2011516603A (en) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． Peptides capable of binding to serum proteins and compounds, constructs and polypeptides containing them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002078A1 (en) * 1989-08-07 1991-02-21 Peptide Technology Ltd Tumour necrosis factor binding ligands
WO2002057445A1 (en) * 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2002079781A1 (en) * 2001-03-28 2002-10-10 Heska Corporation Methods of detecting early renal disease in animals

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D'HAENS G ET AL: "ENDOSCOPIC AND HISTOLOGICAL HEALING WITH INFLIXIMAB ANTI-TUMOR NECROSIS FACTOR ANTIBODIES IN CROHN'S DISEASE: A EUROPEAN MULTICENTER TRIAL", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 116, no. 5, May 1999 (1999-05-01), pages 1029 - 1034, XP009009036, ISSN: 0016-5085 *
ELS CONRATH K ET AL: "Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 10, 9 March 2001 (2001-03-09), pages 7346 - 7350, XP002248402, ISSN: 0021-9258 *
See also references of EP1558647A2 *
TANHA J ET AL: "Selection by phage display of llama conventional VH fragments with heavy chain antibody VHH properties", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER, AMSTERDAM, NL, vol. 263, no. 1-2, 1 May 2002 (2002-05-01), pages 97 - 109, XP004354388, ISSN: 0022-1759 *
VALLE E ET AL: "Infliximab", EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY, LONDON,, GB, vol. 2, June 2001 (2001-06-01), pages 1015 - 1025, XP002965315, ISSN: 1465-6566 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules

Also Published As

Publication number Publication date
EP1900753A2 (en) 2008-03-19
NZ540196A (en) 2008-09-26
EP2284192A2 (en) 2011-02-16
EP2336179A1 (en) 2011-06-22
US20090324512A1 (en) 2009-12-31
EP2301967A2 (en) 2011-03-30
EP2316852A1 (en) 2011-05-04
CA2505326A1 (en) 2004-05-21
EP1900753B1 (en) 2017-08-09
JP2011024581A (en) 2011-02-10
CA2505316A1 (en) 2004-05-21
EP2284192A3 (en) 2011-07-20
US20100021459A1 (en) 2010-01-28
CA2505325A1 (en) 2004-05-21
EP1900753A3 (en) 2008-04-09
US20060115470A1 (en) 2006-06-01
EP2390268B1 (en) 2017-11-01
AU2010226938B2 (en) 2012-03-29
US20100040613A1 (en) 2010-02-18
WO2004041865A3 (en) 2004-07-15
JP2006519763A (en) 2006-08-31
AU2010226938A1 (en) 2010-10-28
EP3299393A1 (en) 2018-03-28
RU2704232C2 (en) 2019-10-24
HK1082745A1 (en) 2006-06-16
IL168357A (en) 2011-09-27
EP2390268A1 (en) 2011-11-30
US9243065B2 (en) 2016-01-26
NZ563471A (en) 2009-04-30
EP2316852B1 (en) 2014-03-05
US20110184145A1 (en) 2011-07-28
CA2505316C (en) 2014-08-05
JP2011256169A (en) 2011-12-22
EP2301967A3 (en) 2011-07-13
JP2006520584A (en) 2006-09-14
US20100003249A1 (en) 2010-01-07
EP2258392A1 (en) 2010-12-08
WO2004041862A2 (en) 2004-05-21
WO2004041863A3 (en) 2004-07-15
MXPA05004955A (en) 2005-11-17
JP2006524036A (en) 2006-10-26
CA2505325C (en) 2014-02-25
NZ540195A (en) 2009-01-31
US20100003248A1 (en) 2010-01-07
NZ540194A (en) 2008-07-31
WO2004041865A2 (en) 2004-05-21
RU2012108416A (en) 2013-09-10
WO2004041863A2 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
WO2004041862A3 (en) Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
NO20052769L (en) The single-domain antibodies directed against tumor necrosis factor-alpha and applications thereof
WO2007022416A3 (en) Single chain antibodies against beta-amyloid peptide
IL245462A0 (en) Humanized anti-cmet antagonists
IL244803A0 (en) Humanized anti-beta7 antibodies and uses therefore
WO2007033221A3 (en) Methods and compositions for inhibition of immune responses
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
WO2006093524A3 (en) Antigen-carbohydrate conjugates
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2007084181A3 (en) Bispecific single chain fv antibody molecules and methods of use thereof
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2007008943A3 (en) Optimized anti-ep-cam antibodies
WO2007141533A3 (en) Fkbp-l and uses thereof
WO2003087131A3 (en) Anti-her2 antibody variants
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
AU2003283136A1 (en) Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
WO2004112829A3 (en) Compositions and methods for the diagnosis and treatment of tumors of glial origin
WO2006069719A3 (en) Lyophilization of virosomes
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors
WO2003075855A3 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 360/MUMNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 168357

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200503618

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2005502085

Country of ref document: JP

Ref document number: 2505316

Country of ref document: CA

Ref document number: PA/A/2005/004955

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020057008180

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006034845

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10534348

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003286002

Country of ref document: AU

Ref document number: 2003776676

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 540194

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2005117634

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 20038A85115

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057008180

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003776676

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0316092

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10534348

Country of ref document: US